1. Pink Sheet
  2. >>Geography
  3. >>Europe

Legislative Overhaul 'Will Not Make EU A Global Leader' In Pharma R&D

Industry Says 'Flexible And Coherent’ Regulatory System Needed

 
• By Ian Schofield

National pricing and reimbursement systems remain a key barrier to medicines access, and requiring companies to market their products in all EU countries and to notify regulators of their launch intentions is not the answer, according to EuropaBio, which represents a wide range of biotech firms operating in Europe.

Extruded political Map of European Union with relief without United Kingdom after anticipated Brexit
The EU is in search of an improved legislative environment for medicines • Source: Alamy

Efforts by the EU authorities to improve the drug regulatory environment have met with a lukewarm response from industry body EuropaBio. It says the proposed revision of the EU pharmaceutical legislation “does not align with the European Commission’s bid to promote the EU as a competitive global leader in biopharmaceutical R&D.”

EuropaBio claims that “little in this revision seeks to address the issues we face for next-generation medicine development, and errs...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

New EFPIA President Hopes ‘Sanity Will Prevail’ In EU Pharma Reform Dialogs

 
• By Eliza Slawther

Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.

UK Pilots Faster Setup Of Early Phase Oncology Trials

 
• By Vibha Sharma

Oncology trial sponsors in the UK are being invited to participate in a pilot that aims to tackle duplication and variation in pharmacy reviews, which are an important part of setting up clinical trials in the National Health Service.

US CDC Vaccine Committee Revives Thimerosal Debate: A Portent Of Things To Come?

 
• By Bridget Silverman

The new Advisory Committee on Immunization Practices voted for new recommendations on the decades-old thimerosal safety issue and lays intellectual groundwork to revisit other past controversies and decisions.